Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Mantle-Cell 5Lymphoma, Non-Hodgkin 4Multiple Myeloma 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, B-Cell 2Waldenstrom Macroglobulinemia 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Lymphoma, Follicular 1Leukemia, Prolymphocytic 1Leukemia, Hairy Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hodgkin Disease 1Chromosome 17 deletion 1Carcinoma, Transitional Cell 1Carcinoma, Non-Small-Cell Lung 1COVID-19 1Burkitt Lymphoma 1Advanced Haematological Malignancies 1

Interventions

acalabrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Haematological Malignancies × acalabrutinib × Clear all
NCT04630756 2025-04-09

AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer

AstraZeneca

Phase 1/2 Completed
40 enrolled 31 charts

Advanced Haematological Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡